Tokai Pharma Begins Phase 2 Clinical Trial for its Castration – Resistance Prostate Cancer Drug

December 14, 2012 by  
Filed under Prostate Cancer News

Tokai Pharmaceuticals Inc. is to carry out a clinical study of it castration-resistance prostate cancer drug – Galeterone.

This study is termed the Androgen Receptor Modulation Optimized for Response (ARMOR) 2 trial. Already, the phase 1 clinical trial has revealed that Galeterone was well-tolerated in patients with this form of advanced prostate cancer.

This clinical trial is going to further evaluate Galeterone, which is a proprietary small molecule with potency of disrupting the growth and survival of prostate tumors.

Ira Kantor highlighted details of this new trial which has been published Thursday, December 13, 2012 in the Boston Herald. Details of the post states the following: Cambridge-based Tokai Pharmaceuticals Inc. said today it is treating the first patient in the company’s ARMOR2 trial, a clinical study of its lead drug candidate Galeterone, which is designed to treat patients with castration-resistant prostate cancer.

credit: google Image

This is the second study in Tokai’s Androgen Receptor Modulation Optimized for Response clinical development program for the evaluation of Galeterone, a proprietary small molecule, oral drug that disrupts the growth and survival of prostate cancer cells.

Results from the ARMOR1 trial showed that Galeterone had clinical activity and was well-tolerated in patients with CRPC, the company said.

Up to 196 patients, including those who are “treatment-naive” and those who have progressed while taking the androgen-directed hormonal therapy, Zytiga, will be enrolled in the ARMOR2 trial, Tokai said.

The company added Galeterone received fast-track designation from the U.S. Food and Drug Administration this year.

Conclusively, we are going to keep tabs with the developments of this clinical trial, and you would be duly informed of the progress made.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)

  1. Phase I Clinical Trial Successful For An Aggressive Prostate Cancer Drug
  2. Enzalutamide Improves Survival for Castration- Resistant Prostate Cancer in Phase III Clinical Trial
  3. Aeterna Zentaris Begins Phase II Study on Prostate Cancer with its Drug AEZS-108
  4. A Clinical Trial Targeting Advanced Prostate Cancer Specifically To Be Carried Out Researchers
  5. Prostate Cancer Treatment – First Clinical Trial for ValiRx’s VAL201 to Commence
  6. Clinical Trial Reveals Revlimid (Lenalidomide) Combination with Other Chemotherapy Drugs Fails as Prostate Cancer Therapy
  7. Genetic Signatures Offer Clues about Prognosis in Castration-Resistance Prostate Cancer
  8. Prostate Cancer Clinical Trials – What You Should Know
  9. Cabozantinib (XL184) effective in Treating Castration-Resistant Prostate Cancer (CRPC) – Study
  10. FDA Expands Approval for Zytiga as Late-Stage Prostate Cancer Drug
  11. Pamorelin LA, a Locally advanced Prostate Cancer Drug Launched in India
  12. New Drug Derived From Poisonous Weed Treats Prostate Cancer
  13. Clinical Trials for Prostate Cancer – Benefits and Risks You Should Know
  14. Cancer Drug New Prostate – New Drug for Prostate Cancer
  15. New Most Powerful Prostate Cancer Drug?

Speak Your Mind

Tell us what you're thinking... !